Sentinels / Actor desk
Society For Tropical Ecology
organization · Registry status: unverified
59e123cc-ee34-5a31-befc-749e2d2cf97a
Evidence, not intent.
Public-source event mentions and stored signals. Adjacency does not establish causation, coordination, or an actor's position.
No claim of complete coverage or live monitoring.
Observation window
UTC dates, inclusive · maximum 90 days. Applies to events and anomalies only.
Recent observations / timeline
The source record
200 distinct events shown, newest first. More matches exist; narrow the dates to inspect beyond the latest 200. Headlines may be generated summaries; inspect the source before repeating a claim.
empr.com: Karim Fizazi, Johnson Johnson, Centre Oscar Lambret (tax disease cancer, wb 1406 diseases)
New targeted drug may reduce endometrial cancer progression and death risk - IrishDentist.ie
Immunotherapy Combo Shows Promise in Rectal Cancer
Prescription EPA was linked to better five-year survival after colorectal cancer liver surgery—but the trial's main endpoint was not met
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
How Charlie's niggling back pain ended up being stage four lung cancer
pharmaceutical-journal.com: Lennard Lee, James Larkin, British Oncology Pharmacy Association (science, tax fncact professor)
ESMO 2026: Phase 3 Study to Assess the Safety and Efficacy of 177Lu-Girentuximab in Advanced, Relapsed or Recurrent ccRCC (LUTEON)
Rethinking Cancer Innovation: How Scientist- and Physician-Led Biotech Is Shaping the Future of Precision Oncology
This week in charts: ESMO’s winners and losers
3 Quality-of-Life Results From ESMO 2026 Patients Should Know | CURE
Omega-3s Might Improve Survival In Advanced Cancer, Trial Finds
empr.com: European Society For Medical Oncology, Melanoma Institute Australia (tax disease cutaneous melanoma, tax disease cutaneous melanoma)
AstraZeneca Q3 Profit Rises; Pipeline Delivers 12 Positive Phase 3 Readouts; Stock Up
Digital CBT Improves Insomnia in Women With Cancer
Sonesitatug Vedotin Improves OS in Gastroesophageal Cancer
AbbVie Reports Third-Quarter 2026 Financial Results
AbbVie Reports Third-Quarter 2026 Financial Results
Regeneron Reports Third Quarter 2026 Financial and Operating Results
ESMO 2026: A Phase 1 Study of GB-4362, a Free MMAE-Neutralizing Antibody, With Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Cancer
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
Less Frequent ICI Therapy Fails in Trial but Offers Lessons
Osimertinib-Savolitinib Boosts Survival in MET+ NSCLC
Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Pharmaceutical Company Limited: Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
Is Exercise Changing Cancer Care?
urotoday.com: Deepak Kilari, Julian Chavarriaga, European Society For Medical Oncology (soc pointsofinterest college, education)
Amarin (AMRN) Q3 2026 Earnings Call Transcript | The Motley Fool
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
A Cancer Vaccine Custom-Made from Each Patient’s Own Tumor Reduced Melanoma Recurrence Risk by 42 Percent
What New KRAS Drug Data From ESMO 2026 Mean for Patients | CURE
Imdelltra Plus Imfinzi Extends Survival in Small Cell Lung Cancer | CURE
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
New test could flag which men need aggressive prostate cancer treatment and which don't
New drug boosts survival from hard-to-treat uterine cancer
pmlive.com: Levi Garraway, Ferdinandos Skoulidis, Drug Administration (tax disease nsclc, tax disease nsclc)
ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
New drug boosts survival from hard-to-treat uterine cancer
TransCode Reports Phase 1a Data For TTX-MC138 In Advanced Solid Tumors
BriaCell Bets an Off-the-Shelf Cell Vaccine Can Extend Life After ADCs in Metastatic Breast Cancer | AJMC
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
New drug boosts survival from hard-to-treat uterine cancer
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
New drug boosts survival from hard-to-treat uterine cancer
Nuvectis' NXP200 Shows Complete Responses In BRAF-Mutated Recurrent Gliomas
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
New Christian Communities – new light: ways ahead in Christian unity?
Sone-ve: Stomach cancer drug extends overall survival - ARY NEW
MacroGenics Expands Lorigerlimab Trial After Interim Gynecologic Cancer Results; Stock Down
Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
Genmab's Potesemtamab Plus Pembrolizumab Shows 28-Month Survival In Head And Neck Cancer
J&J's RYBREVANT FASPRO Combo Delivers 77% Response Rate In Head And Neck Cancer
AstraZeneca's Sone-Ve Cuts Death Risk By 42% In Advanced Gastric Cancer Trial; Stock Up
AstraZeneca's Tagrisso Combo Achieves Significant Survival Benefit In Lung Cancer Trial; Stock Up
Parabilis Medicines Reports 72% Response Rate For Zolucatetide In Desmoid Tumors; Stock Down
Amgen drug combined with immunotherapy extends survival in lung cancer trial
New Canadian Real-World Evidence at ESMO 2026 Highlights Integration of CLDN18.2 Testing and Targeted Treatment in Clinical Practice
New Canadian Real-World Evidence at ESMO 2026 Highlights Integration of CLDN18.2 Testing and Targeted Treatment in Clinical Practice
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Novastra Therapeutics Reports Encouraging First Clinical Data for Its Novel XIRT™/OAP Cancer Immune Therapy at ESMO Congress 2026
Breakfast News: Science Strikes Back at Cancer | The Motley Fool
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
New lung cancer drug adds nearly six months of survival; stomach cancer treatment doubles it
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026 | Newswise
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity – Thailand Business News
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
Microbiotica Presents Phase 1b Clinical Data on MB097 at the European Society for Medical Oncology (ESMO) Congress 2026
PureTech Health plc: PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
Next generation KRAS inhibitor divarasib significantly extends lung cancer survival
Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026
North South University Hosts the ESMO Examination 2026 in Bangladesh for the Second Time - The Bangladesh Today
urotoday.com: Neoadjuvant Enfortumab Vedotin, Neoadjuvant Enfortumab Vedotin, Neoadjuvant Enfortumab Vedotin (medical, medical)
Johnson & Johnson Reports 75% Tumor Response Rate in Advanced Prostate Cancer with JNJ-6143, a First-in-Class RIPTAC™ Molecule
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy
Eli Lilly reports promising lung cancer drug results (LLY:NYSE)
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine - Australian Bloggers
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy
Immunotherapy Combo Improves Bladder Cancer EFS
Personalized Melanoma Vaccine Improves RFS in Phase 3 Trial
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
ESMO 2026: New Targeted Therapy Improved Survival for Patients with KRAS-Mutated Lung Cancer | Newswise
Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
F. Hoffmann-La Roche Ltd: Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
ESMO 2026: UT MD Anderson highlights innovative approaches to monitor, prevent and treat cancer | Newswise
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO – Thailand Business News
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine – Thailand Business News
ESMO 2026: Prognostic Utility of Circulating Tumor Cell (CTC) Count, CTC Conversion, and CTC0 in TALAPRO-3
Pfizer's Atirmociclib Held Off Breast Cancer Progression for 9.4 Months Versus 6.6 After CDK4/6 Drugs Stopped Working
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Ivonescimab Beat Imfinzi Regimen on Survival in China Bile Duct Cancer Trial, Akeso Says, as Details Await ESMO
Agenus Inc.: Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Genmab A/S: Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Amgen drug combined with immunotherapy extends survival in lung cancer trial
Kelun Reports Longer Survival With Sac-TMT in Final OS Analysis of OptiTROP-Lung04 | EconoTimes
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy | Company Announcement | Investegate
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC – Thailand Business News
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer – Thailand Business News
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
BioNTech SE: BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
ESMO 2026: Is Less Enough and More Too Much? Implications of VOLGA for the Peri-Operative Therapeutic Landscape in MIBC
ESMO 2026: Novel Agents in Rare Cancers
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study
Is Active Surveillance Feasible for Esophageal Cancer?
Novel ADC Extends PFS in HER2-Low Breast Cancer
Doctors cheer while investors bounce over cancer vaccine
Lung cancer breakthrough: drug combination cuts death risk by 58% in major trial
Johnson & Johnson Reports Early JNJ-6143 Responses in Prostate Cancer Trial | EconoTimes
Personalized mRNA Melanoma Vaccine Cut Recurrence or Death Risk 42% in Phase 3 Trial, but Survival Data Pending
Amgen drug paired with immunotherapy improves survival in lung cancer trial: report
moneycontrol.com: Joaquim Bellmunt, David Fredrickson, Amgen Burton (crisislex c03 wellbeing health, crisislex c03 wellbeing health)
AstraZeneca: Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO - Australian Bloggers
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Amgen drug combined with immunotherapy extends survival in lung cancer trial
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO – Thailand Business News
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Orion Oyj: Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Farmers & Merchants Investments Inc. Acquires 5,107 Shares of Abbott Laboratories $ABT
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Medicines Ltd.: BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Orion Oyj: Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
Eli Lilly and Company: Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRa-targeting ADC at ESMO 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Signals to inspect
Anomalies
Latest 10 in the selected window (up to 10). Detector output, not verified conclusions.
New connection: 3 previously unseen co-actor(s) detected (known network: 148)
New connection: 3 previously unseen co-actor(s) detected (known network: 145)
New connection: 1 previously unseen co-actor(s) detected (known network: 144)
New connection: 15 previously unseen co-actor(s) detected (known network: 131)
New connection: 5 previously unseen co-actor(s) detected (known network: 128)
New connection: 4 previously unseen co-actor(s) detected (known network: 124)
New connection: 4 previously unseen co-actor(s) detected (known network: 121)
New connection: 7 previously unseen co-actor(s) detected (known network: 114)
New connection: 7 previously unseen co-actor(s) detected (known network: 107)
Narrative context
Unresolved threads
Latest 20 at most, across all dates. Stored narratives require human review.
Stored connections
Relationships
Up to 50 records ordered by evidence count, across all dates. Co-mentions indicate association in source material, not affiliation or coordination.
- Drug Enforcement Administration→ co mention →Society For Tropical Ecology70 evidence records
- Society For Tropical Ecology→ co mention →United States Senate60 evidence records
- Society For Tropical Ecology→ co mention →Nasdaq46 evidence records
- Society For Tropical Ecology→ co mention →Securities and Exchange Commission44 evidence records
- Society For Tropical Ecology→ co mention →Terms Of Service43 evidence records
- Society For Tropical Ecology→ co mention →Linkedin42 evidence records
- Society For Tropical Ecology→ co mention →Md Anderson Cancer Center29 evidence records
- Society For Tropical Ecology→ co mention →Chinese National Medical Products Administration28 evidence records
- Society For Tropical Ecology→ co mention →American Society Of Pediatric Hematology Oncology24 evidence records
- Thoraia Hussein→ co mention →Society For Tropical Ecology24 evidence records
- Society For Tropical Ecology→ co mention →Keytruda Qlex24 evidence records
- Society For Tropical Ecology→ co mention →National Reimbursement Drug List Of China21 evidence records
- Facebook→ co mention →Society For Tropical Ecology20 evidence records
- Society For Tropical Ecology→ co mention →Astrazeneca20 evidence records
- Society For Tropical Ecology→ co mention →Tony Vastenhout20 evidence records
- Society For Tropical Ecology→ co mention →Kunle Oyekanmi20 evidence records
- Society For Tropical Ecology→ co mention →Associated Press20 evidence records
- Society For Tropical Ecology→ co mention →European Union16 evidence records
- Instagram→ co mention →Society For Tropical Ecology16 evidence records
- Society For Tropical Ecology→ co mention →Daiichi Sankyo15 evidence records
- National Cancer Institute Of Kenya Ncikenya→ co mention →Society For Tropical Ecology14 evidence records
- Society For Tropical Ecology→ co mention →Jazz Pharmaceuticals News Roundup14 evidence records
- Society For Tropical Ecology→ co mention →Eli Lilly13 evidence records
- Eboog Johnson→ co mention →Society For Tropical Ecology13 evidence records
- Prnewswire Telix Pharmaceuticals Limited→ co mention →Society For Tropical Ecology12 evidence records
- Society For Tropical Ecology→ co mention →Yanni Jason12 evidence records
- Society For Tropical Ecology→ co mention →American Associated Of Cancer Research12 evidence records
- Society For Tropical Ecology→ co mention →Youtube11 evidence records
- Prnewswire Kia Europe→ co mention →Society For Tropical Ecology10 evidence records
- Society For Tropical Ecology→ co mention →Jung Hoo Lee10 evidence records
- Society For Tropical Ecology→ co mention →Diana Papove10 evidence records
- Society For Tropical Ecology→ co mention →Corporate Communications Department10 evidence records
- Amgen→ co mention →Society For Tropical Ecology10 evidence records
- Society For Tropical Ecology→ co mention →World Health Organization9 evidence records
- Society For Tropical Ecology→ co mention →American Cancer Society Georgia Area9 evidence records
- Society For Tropical Ecology→ co mention →Yale Cancer Center Early Onset Cancer8 evidence records
- Shreeram Inamdar→ co mention →Society For Tropical Ecology8 evidence records
- Sabeen Mekan→ co mention →Society For Tropical Ecology8 evidence records
- Early Clinical Development→ co mention →Society For Tropical Ecology8 evidence records
- Society For Tropical Ecology→ co mention →Pfizer8 evidence records
- Society For Tropical Ecology→ co mention →Bristol Myers Squibb8 evidence records
- Sun Pharmaceuticals On→ co mention →Society For Tropical Ecology8 evidence records
- Society For Tropical Ecology→ co mention →Zymeworks Inc7 evidence records
- Liza Helies→ co mention →Society For Tropical Ecology7 evidence records
- Society For Tropical Ecology→ co mention →University Hospitals Seidman Cancer Center7 evidence records
- Stock Exchange Of Hong Kong Limited Hkex→ co mention →Society For Tropical Ecology7 evidence records
- Society For Tropical Ecology→ co mention →Jason Ader William Blair7 evidence records
- Society For Tropical Ecology→ co mention →Merck Sharp Dohme6 evidence records
- Chevron→ co mention →Society For Tropical Ecology6 evidence records
- Shell→ co mention →Society For Tropical Ecology6 evidence records